TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03855566

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intensive behavioral therapy for obesity
Description: Approximately 24, 20 minute sessions over 12 months focused on diet and physical activity behavior change goals to promote weight loss. Framework includes health belief model, transtheoretical model and motivational interviewing.
Study: NCT02188719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
Study: NCT01212315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan coated sutures
Description: Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
Study: NCT00484432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 week until confirmed evidence of disease progression or unacceptable toxicity occurs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Doxorubicin: 60mg/m² every 3 weeks, until cumulative dose of 550 mg/m²
Study: NCT02266303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin Start-up Checklist
Description: The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
Study: NCT01149746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Test 0.4 mg Capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Reference Listed 0.4 mg Capsule
Study: NCT03680807

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle function test
Description: Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle function test
Description: Power and strength tests of the knee-extensor muscles, handgrip strength, functional capacity tests
Study: NCT01497197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GONAL-f®
Description: GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GONAL-f®
Description: GONAL f® 300 international units \[IU\] per day as subcutaneous injection using liquid pen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris®
Description: Luveris® 150 IU per day lyophilized powder for subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveris®
Description: Luveris® 150 IU per day lyophilized powder for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
Study: NCT00873925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous UCB
Description: Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 FA
Description: Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
Study: NCT01136603

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TIGR Mesh
Description: TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TIGR Mesh
Description: TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
Study: NCT01682109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Study: NCT02545439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet given alone and in conjunction with Rifampin
Study: NCT01622296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: 8.4% neutralizing solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine with 1:100,000 ppm epinephrine
Study: NCT02896257

Intervention type: OTHER
Group type: OTHER
Intervention: Guideline treatment recommendations
Description: Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
Study: NCT02394821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polihexanide 2%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole 0.8%
Study: NCT00371371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow punction
Description: A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bone marrow punction
Description: A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BM-MNC infusion
Description: Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Description: Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
Study: NCT03454230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positioning schedule
Description: Applying repositioning schedule daily adapted to pressure ulcer risk assessed with Braden scale. Then, the nurse will applied oil for PU prevention and repositioning which frequency will be defined by the Braden score. The positions will be the semi-fowler 30-30, the half-sitting position with a 45° angle position and patient lying on their back with the head up with a 30° angle for ventilator associated pneumonia prevention.~Repositioning schedule will be applied according to the daily medical prescription. When physician allows to sit the patient on a chair, this have to be done by raising feet on a stool. Therefore, patients will stay in that chair as long as defined by positioning schedule. When patient is returned to bed, same positions as described above will be used alternately. In the time of positioning care, oil usually used for PU prevention will be applied on the skin of the areas of high risk of PU (heels, sacrum, elbows, trochanter, knees) and bone projections.
Study: NCT04444089

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound with a curvilinear probe (DDED) is performed in all patients in a supine position on the lateral wall of the chest at approximately the level of the lower ribs using an ultrasound probe at a frequency of 4-12 MHz (AcusonX300, Siemens Korea, Seoul, South Korea). The mean number of B-lines detected on the ultrasound image and the percentage of patients who showed B-lines on their images were recorded. The mean of three measurements is used. Inter-observer variability is estimated to be 0.766 (95% confidence interval 0.675-0.847).
Study: NCT01781884

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Aminobutyric Acid (GABA)
Description: two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Aminobutyric Acid (GABA)
Description: two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04446403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block
Description: The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular Nerve Block
Description: The patient will be put in sitting down position with upper limbs pending beside the body then a high-frequency linear ultrasound probe will be positioned transversely above the spine of the scapula. The suprascapular nerve often appears as hypereccoic structure at the suprascapular notch. A 20-gauge spinal needle will be advanced in-plane from medial to lateral 10mL of bupivacaine 0.25% into the suprascapular notch deep to the superior transverse scapular ligament (STSL) and adjacent to the suprascapular artery (SSA) .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Nerve Block
Description: Patient will be put in sitting position, with the shoulder in full adduction. linear transducer (8-14 MHz) will be positioned in the short axis orientation at the neck of humerous to identify the axillary artery about 1 to 3 cm from the skin surface.The artery is the most reliable landmark, then a 21-gauge 90 mm needle will be advanced in-plane and 10 mL of bupivacaine 0.25% will be injected adjacent to the artery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior cord block
Description: Patient will be put in supine position with head turned away from side that will be blocked with the arm abducted 90 and flexed at the elbow then linear transducer (8-14 MHz) will be positioned in short-axis just medial to coracoid process.Once the artery will be identified, an attempt will be made to identify the hyperechoic cords of the brachial plexus and their corresponding positions relative to the artery, although these may not always be identifiable. The needle will be inserted in plane from the cephalad end of the probe. 10 mL bupivacaine 0.25% will be injected at the posterior cord.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anaesthesia will be induced after giving nerve block in a standardized way with propofol 1.5-2.5mg/kg, fentanyl 2-3 µ/kg and atracurium 0.5mg/kg. maintenance of anaesthesia with isoflurane and atracurium 0.1mg/kg/20min.
Study: NCT02112643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium selenate
Description: A 100 microgram pill will be orally administered twice a day for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
Study: NCT01979614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serelaxin
Description: Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5% v/v glucose solution
Study: NCT00790049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor; oral
Description: single dose and multiple dose, escalating

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; oral
Description: matching placebo
Study: NCT00488514

Intervention type: DRUG
Group type: OTHER
Intervention: Combination Tablet of Treximet (sumatriptan/naproxen sodium)
Description: Combination Tablet of Treximet(sumatriptan/naproxen sodium)
Study: NCT00730756

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Furoate Nasal Spray
Description: Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: Matching placebo nasal spray intranasally once daily for 4 weeks
Study: NCT02188719

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
Study: NCT01641107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Treatment:~Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion.
Study: NCT00517699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: 750mg/m2 iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 8g/m2 iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 2g/m2 iv
Study: NCT01102595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: * Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: * Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: * 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~* Bevacizumab 10 mg/kg every 15 days, three dosis.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy
Description: 42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiation therapy
Description: 42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
Study: NCT02629926

Intervention type: OTHER
Intervention: GH Replacement (NutropinAq®)
Description: GH Replacement continued.

Intervention type: OTHER
Intervention: No additional treatment
Description: GH Replacement not continued.
Study: NCT03571932

Intervention type: BEHAVIORAL
Intervention: Family planning and immunization service integration
Description: The approach involved integration of immunization and family planning services at health facilities. Vaccinators provided brief FP messages one-on-one to mothers and offered a referral for same-day, co-located FP services at the end of each routine immunization visit. For women coming directly for FP, if women had an infant with them, FP providers asked to see the child's health card, checked the return date for the next vaccination and reminded the mother of the date to return. For women without their child or the child health card with them, FP providers reinforced the importance of vaccination, and encouraged the mothers to bring their child for all their vaccines and complete the immunization schedule in a timely manner. A job aid, referral cards, and IEC materials were introduced to support the integration process.
Study: NCT01446874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution
Description: Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution
Description: Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine solution
Description: Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
Study: NCT00638729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inert tablet p.o., 60-90 min prior to estimated induction time
Study: NCT04420858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced (experimental) education
Description: See arm description.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard (control) education.
Description: See arm description.
Study: NCT03186105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulatory appendicectomy
Description: The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
Study: NCT02535897

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flavoured water

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavoured water + carbohydrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flavoured water + carbohydrate + protein